|
|
| Line 153: |
Line 153: |
| | </td> | | </td> |
| | </tr> | | </tr> |
| | + | |
| | + | <tr><td align=center valign=center> |
| | + | <h3>CascAID</h3> |
| | + | <p> |
| | + | Our project, which we named Cas13a controlled assay for infectious diseases (CascAID), features the recently identified CRISPR/Cas effector Cas13a10. Unlike other proteins in the familiy, Cas13a has the unique ability to bind and cleave specific RNA targets rather than DNA ones. Moreover, after cleaving its target, Cas13a is able to unspecifically cleave RNA molecules. By using this collateral activity from Cas13a, our system is capable of detecting virtually any RNA target. This is done by changing the crRNA in the protein, that is a short RNA sequence that determines what is recognized as target.</p> |
| | + | </td> |
| | + | <td align=center valign=center> |
| | + | <a href="https://www.uni-muenchen.de/index.html"><img src="https://static.igem.org/mediawiki/2017/0/0d/T--Munich--Logo_LMU.png" width="270"></a> |
| | + | </td> |
| | + | |
| | + | </tr> |
| | | | |
| | <tr><td colspan=3 align=center valign=center> | | <tr><td colspan=3 align=center valign=center> |
| Line 161: |
Line 172: |
| | </td> | | </td> |
| | </tr> | | </tr> |
| − |
| |
| − |
| |
| | | | |
| | <tr><td class="no-padding" colspan=2 align=right valign=center height=10> | | <tr><td class="no-padding" colspan=2 align=right valign=center height=10> |
|
| |
|
|
|
Description
|
|
Thanks to advances in molecular biology and biochemistry, scientists have been able to consistently detect lower and lower concentration of molecules1, to the point that single molecules can be reliably recognized with methods such as polymerase chain reaction (PCR)2, fluorescence in situ hybridization (FISH)3 and enzyme-linked immunosorbent assays (ELISA)4. This has opened doors for synthetic biology to create better and more accurate diagnostic tests that use biomarkers like nucleic acids and proteins as targets5,6. Through such advances, the field of molecular diagnostics developed. Unfortunately, current standard methods require expensive equipment or trained personnel, which generally limits their usability to hospitals or laboratories. Recently, there has been a push to develop new tests that fuse the reliability of standard methods with affordable platforms such as lab-on-a-chip or paper strips to overcome this restrictions7-9. We wanted to help close this gap and set out to engineer a diagnosis principle for the detection of a wide array of targets that could be used without difficult-to-meet technical requirements..
|
CascAID
Our project, which we named Cas13a controlled assay for infectious diseases (CascAID), features the recently identified CRISPR/Cas effector Cas13a10. Unlike other proteins in the familiy, Cas13a has the unique ability to bind and cleave specific RNA targets rather than DNA ones. Moreover, after cleaving its target, Cas13a is able to unspecifically cleave RNA molecules. By using this collateral activity from Cas13a, our system is capable of detecting virtually any RNA target. This is done by changing the crRNA in the protein, that is a short RNA sequence that determines what is recognized as target.
|
|
Organization
As our team was composed of people with different lab-experience, there were some members who instructed the others in the use of lab equipment and methods. Our master students, Max, Ludwig and Sven teached the other team members and coordinated work distribution. Our supervisors Lukas and Aurore took over responsibility, supported the team in each point of this project and invested a lot of time in and outside the lab.
|
|
|
|
|
|
| |
